Programmed cell death

Transplantation

Volumn 66, Issue 6, 1998, Pages 681-691

  Woodle, E Steve ^a   Kulkarni, Sanjay ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL DESTRUCTION; CELL NUCLEUS; CELL ULTRASTRUCTURE; DNA DEGRADATION; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; HUMANS;

EID: 0032572973     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809270-00001     Document Type: Review

References (133)

1. Golstein P, Ojcius DM, Young DE. Cell death mechanisms and the immune system. Immunol Rev 1991; 121: 30.
2. Earnshaw WC. Nuclear changes in apoptosis. Curr Opin Cell Biol 1995; 7: 337.
3. Ashkenas J, Werb Z. Proteolysis and the biochemistry of life-or-death decisions. J Exp Med 1996; 183: 1947.
4. Howie SEM, Harrison DJ, Wyllie AH. Lymphocyte apoptosis: mechanisms and implications in disease. Immunol Rev 1994; 142: 141.
5. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119.
6. Zamzami N, Susin SA, Marchetti P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med 1996; 183: 1533.
7. Zamzami NP, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182: 367.
8. Castedo M, Hirsch T, Susin SA, et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 1996; 157: 512.
9. Kroemer G, Petit PX, Zamzami N, Vayssiere JC, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995: 9: 1277.
10. Zamzami N, Marchetti P, Castedo M, et al. Reductions in mitochondrial potential constitute an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181: 1661.
11. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 1997; 275: 1132.
12. Hughes FM, Cidlowski JA. Utilization of an in vitro assay to evaluate chromatin degradation by candidate apoptotic nucleases. Cell Death Diff 1997; 4: 200.
13. Hughes FM, Cidlowski JA. Apoptotic DNA degradation: evidence for novel enzymes. Cell Death Diff 1994; 1: 11.
14. Schwartzman RA, Cidlowski JA. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev 1993; 14: 133.
15. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555.
16. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984; 132: 38.
17. Oberhammer F, Wilson JW, Dive C, et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993; 12: 3679.
18. Walker PR, Kokileva L, LeBlanc J, Sikorska M. Detection of the initial stages of DNA fragmentation in apoptosis. Biotechniques 1993; 15: 1032.
19. Kokileva L. Multi-step chromatin degradation in apoptosis. Int Arch Allergy Immunol 1994; 105: 339.
20. 2+ alone. FEBS Lett 1994; 349: 385.
21. Beere HM, Chresta CM, Alejoherberg A, et al. Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis. Mol Pharmacol 1995; 47: 986.
22. Cohen GM, Sun XM, Fearnhead H, et al. Formation of large molecular weight fragments of DNA is a key committed step of apoptosis in thymocytes. J Immunol 1994; 153: 507.
23. Omerod MG, O'Neill CF, Robertson D, Harrap KR. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 1994; 211: 231.
24. Komiyama T, Quan LT, Salvesen GS. Inhibition of cysteine and serine proteinases by the cowpox virus serpin CRMA. Adv Exp Med Biol 1996; 389: 173.
25. Hengartner MO, Horvitz RH. The ins and outs of programmed cell death during C. elegans development. Philos Trans R Soc Lond B Biol Sci 1994; 345: 243.
26. Ellis HM, Horvitz RH. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817.
27. Hengartner MO, Horvitz HR. Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 1994; 4: 581.
28. Yuan J, Shaham S, Ledoux S, Ellis H, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993; 75: 641.
29. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin 1-β processing in monocytes. Nature 1992; 356: 768.
30. Wilson KP, Black JAF, Thomson JA, et al. Structure and mechanism of interleukin-1β converting enzyme. Nature 1994: 370:270
31. Kumar S, Lavin MF. The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ 1996; 3: 255.
32. Shi L, Chih-Min K, Powers JC, Aebersold R, Greenberg AH. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 1992; 176: 1521.
33. Odake S, Kan CM, Narasimhan L, et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 1991; 30: 2217.
34. Caputa A, James MN, Powers JC, Hudig D, Bleackley RC. Conversion of the substrate specificity of mouse proteinase granzyme B. Nat Struct Biol 1994; 1: 364.
35. Sleath PR, Hendrickson RC, Krohnheim SR, March CJ, Black RA. Substrate specificity of the protease that processes human interleukin-1 beta. J Biol Chem 1990; 265: 14526.
36. Gagliardini V, Fernandez PA, Lee RKK, et al. Prevention of vertebrate neuronal death by crmA gene. Science 1994; 263: 826.
37. Miura M, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1β converting enzyme, a mammalian homologue of the C. elegans cell death gene ced-3. Cell 1993; 75: 653.
38. Strasser A, Harris AW, Huang DCSA, Krammer PH, Cory S. Bcl-2 and Fas/Apo-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136.
39. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78.
40. Los M, Van de Craen M, Penning LC, et al. Requirement of an ICE/Ced-3 protease for Fas/Apo-1-mediated apoptosis. Nature 1995; 375: 81.
41. Beyaert R, Kidd VJ, Cornelis S, et al. Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor. J Biol Chem 1997; 272: 11694.
42. Dbaibo GS, Perry DK, Gamard CH, et al. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-alpha: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 1997; 185: 481.
43. + T cells is induced by some combinations of anti-CD2 mAb. J Immunol 1993; 151: 3547.
44. Geley S, Harmann BL, Kapelari K, et al. The interleukin 1 beta-converting enzyme inhibitor CrmA prevents Apol/Fas-but not glucocorticoid-induced poly (ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Lett 1997; 402: 36.
45. Trauth BC, Klaus C, Peters AM, et al. Monoclonal-antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301.
46. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell-surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747.
47. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233.
48. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992; 267: 10709.
49. Itoh N, Yonehara A, Ishii A, et al. The polypeptide encoded by the cDNA for the human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233.
50. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily in normal and neoplastic cells. Lab Invest 1993; 69: 415.
51. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169.
52. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 873.
53. Tartaglia LA, Ayres TM, Wang GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1994; 76: 959.
54. Golstein PO, Marguet D, Depraetene V. Homology between reaper and the cell death domains of Fas and TNFR1. Cell 1995; 81: 185.
55. Huang B, Eberstadt M, Olejwiczak ET, Meadow RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384: 638.
56. Alderson MR, Armitage RJ, Marakovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231.
57. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795.
58. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505.
59. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961.
60. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/ced-3 like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817.
61. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495.
62. Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995; 358: 113.
63. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995; 267: 1494.
64. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579.
65. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803.
66. Scaffidi C, Fuldo S, Srinivasan A. Two CD95 (APO-1/Fas) signalling pathways. EMBO J 1998; 17: 1675.
67. Thome M, Schneider P, Hoffmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517.
68. Bodmer JL, Burns K, Schneider P, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas (APO-1/CD95). Immunity 1997; 6: 79.
69. Marsters SA, Sheridan JP, Donahue CJ, et al. APO-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NFκB. Curr Biol 1996; 6: 1669.
70. Kitson J, Raven T, Jiang YP, et al. A death-domain containing receptor that mediates apoptosis. Nature 1996; 384: 372.
71. Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNF-RI and CD95. Science 1996; 274: 990.
72. Lee SY, Lee SY, Choi Y. A novel component of the TNFR- and CD30-TRAF signaling complex that inhibits TRAF2-mediated NF-κB activation. J Exp Med 1997; 185: 1275.
73. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 274: 782.
74. Schutze S, Machleidt T, Kronke M. The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 1994; 56: 533.
75. Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995; 20: 73.
76. Haimovitz-Friedman A, Kan C, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180: 525.
77. Jayadev S, Liu B, Bielawska AE, et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995; 270: 2047.
78. Gottschalk AR, McShan CL, Kilkus J, Dawson G, Quintans J. Resistance to anti-IgM-induced apoptosis in a WEHI-231 subline is due to insufficient production of ceramide. Eur J Immunol 1995; 25: 1032.
79. Boucher LM, Wiegmann K, Futterer A, Pfeffer K, Mak TW, Kronke M. CD28 signals through acidic sphingomyelinase. J Exp Med 1995; 181: 2059.
80. Mathias S, Younes A, Kan CC, Orlow I, Joseph C, Kolesnick RN. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science 1993; 259: 519.
81. Dobrowsky RT, Hannun YA. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 1992; 267: 5048.
82. Lozano J, Berra E, Municio MM, et al. Protein kinase C isoform is critical for κB-dependent promoter activation by sphingomyelinase. J Biol Chem 1994; 269: 19200.
83. Gulbins E, Bissonnette R, Mahboubi A, et al. Fas-induced apoptosis is mediated via a ceramide-initiated Ras signaling pathway. Immunity 1995; 2: 1.
84. Coroneos E, Wan Y, Panuska JR, Templeton DJ, Kester M. Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochem J 1996; 316: 13.
85. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381: 800.
86. Pyne S, Chapman J, Steele L, Pyne NJ. Sphingomyelin-derived lipids differentially regulate the extracellular signal-regulated kinase 2 (ERK-2) and c-June N-terminal kinase (JNK) signal cascades in airway smooth muscle. Eur J Biochem 1996; 237: 819.
87. Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995; 270: 22689.
88. Woodle ES, Smith DM, Bluestone JA, Kirkman WM, Green DR, Skowronski EW. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the fas-antigen-mediated pathway. J Immunol 1997; 158: 2156.
89. kck tyrosine kinases, leads to an alternate phenotype of the TCR/CD3 ζ chain, and induces apoptosis. J Immunol 1997; 158: 3189.
90. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19.
91. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214.
92. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J Immunol 1990; 144: 3602.
93. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334.
94. Chen-Levy Z, Nourse J, Cleary ML. The Bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18). Mol Cell Biol 1989; 9: 701.
95. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361: 365.
96. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609.
97. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by anti-apoptotic protein, Bcl-2. Proc Natl Acad Sci USA 1997; 94: 5113.
98. Shaham S, Horvitz HR. Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. Genes Dev 1966; 10: 578.
99. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of ced-4 with ced-3 and ced-9: a molecular framework for cell death. Science 1997; 275: 1122.
100. Wu P, Wallen HD, Nunez G. Interaction and regulation of subcellular localization of ced-4 by ced-9. Science 1997; 275: 1126.
101. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597.
102. Bergese SD, Klenotic SM, Wakely ME, Sedmak DD, Orosz CG. Apoptosis in murine cardiac grafts. Transplantation 1997; 63: 320.
103. Bergese SD, Klenotic SM, Wakely ME, Sedmak DD, Orosz CG. Apoptosis in murine cardiac grafts. Transplantation 1997; 63: 320.
104. White WL, Zhang YL, Shelby J, et al. Myocardial apoptosis in a heterotopic murine heart transplantation model of chronic rejection and graft vasculopathy. J Heart Lung Transplant 1997; 16: 250.
105. Lagueris RP, Meckert PM, Martino JS, Perrone S, Favaloro R. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996; 15: 911.
106. Krams SM, Egawa H, Quinn MB, Villanueva JC, Garcia-Kennedy R, Martinez OM. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation 1995; 59: 621.
107. Qian S, Lu L, Fu F, et al. Apoptosis within spontaneously accepted mouse liver allografts. J Immunol 1997; 158: 4654.
108. Afford SC, Hubscher S, Strain AJ, Adams DH, Neuberger JM. Apoptosis in the human liver during allograft rejection and end-stage liver disease. J Pathol 1995; 176: 373.
109. Lee RG, Nakamura K, Tsamandas AC, et al. Pathology of human intestinal transplantation. Gastroenterology 1996; 110: 1820.
110. Laine J, Etalamaki P, Holmberg C, Dund L. Apoptotic cell death in human chronic renal allograft rejection. Transplantation 1997; 63: 101.
111. Sambhara SR, Miller RG. Programmed cell death of T cells signaled by the T cell receptor and the alpha3 domain of class I MHC. Science 1991; 252: 1424.
112. Miller RG, Derry H. A cell population in nu/nu spleen can prevent generation of cytotoxic lymphocytes by normal spleen cells against self antigens of the nu/nu spleen. J Immunol 1979; 122: 1502.
113. Claesson MH, Miller RG. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong anti-self suppressive activity. J Exp Med 1984; 160: 1702.
114. Fink PJ, Rammensee HG, Benedetto JD, Staerz UD, Lefrancois L, Bevan MJ. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J Immunol 1984; 133: 1769.
115. Zhang L, Shannon J, Sheldon J, Teh HS, Mak TW, Miller RG. Role of infused CD8+ cells in the induction of peripheral tolerance. J Immunol 1994; 152(5): 2222.
116. Carlow DA, Teh SJ, van Oers NS, Miller RG, Teh HS. Peripheral tolerance through clonal deletion of mature CD4-CD8+ T cells. Int Immunol 1992; 4(5): 599.
117. Zhang LI, Martin DR, Fung-Leung WP, Teh HS, Miller RG. Peripheral deletion of mature CD8+ antigen-specific T cells after in vivo exposure to male antigen. J Immunol 1992; 148(12): 3740.
118. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
119. Vaux DL. Immunology: ways around rejection. Nature 1995; 377: 576.
120. Yagita H, Senok, Kayagaki N, Okumuura K. CD95 ligand in graft rejection. Nature 1996; 379: 682.
121. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
122. Stuart PM, Griffith TS, Usui N, Depose J, Yu Y, Ferguson TA. CD95 ligand (Fas L)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396.
123. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 1993; 2: 123.
124. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing Fas L in mice. Science 1996; 273: 109.
125. Yogota H, Kayaleyo N, Okumuura K. CD95 ligand in graft rejection. Nature 1996; 379: 687.
126. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182: 1777.
127. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84: 1201.
128. Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995; 86: 1437.
129. Allison J, Georgiou HM, Strassen A, Vaux DL. Transgenic expression of CD95 ligand on islet B cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
130. Muruve DA, Nicolson AG, Manfro RC, Strom TB, Sychatrone YP, Liebermann TA. Adeno virus-mediated suppression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of in-vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther 1997; 8: 955.
131. Kang SM, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
132. Statter MB, Foglia RP, Parks DE, Donahoe PK. Fetal and postnatal testis shows immunoprivilege as donor tissue. J Urol 1988; 139: 204.
133. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J Immunol 1995; 155: 4147.